In a nutshell
This study aimed to investigate the link between PSA (prostate-specific antigen) levels and prostate cancer (PCa) prognosis. This study found that a lower PSA level (less than 0.2ng/ml) was associated with less risk of dying from PCa.
Some background
The PSA is a substance produced by the prostate. It can be used as a marker during the treatment of PCa. It is unclear if the speed of a fall in PSA has prognostic value.
Methods & findings
This study included 204 men. They had radiation therapy with or without 6 months of androgen deprivation therapy (ADT; hormonal therapy). ADT stops the production of testosterone which helps PCa to grow. They were followed up for an average of 18.17 years.
Men with PSA levels greater than 0.2 ng/ml had a higher risk of dying from PCa. This was not seen in men with PSA less than 0.2 ng/ml. Men whose PSA level dropped quickly also had less risk of dying from PCa.
The bottom line
This study found that a lower PSA level (less than 0.2ng/ml) was associated with less risk of dying from PCa.
The fine print
This study included a small number of high-risk patients. Larger studies are still needed.
Published By :
Urology
Date :
Jan 18, 2019
